Risk factor
Very high price volatility
Profitability factor
Very unfavourable price performance
About
I'rom Group Co., Ltd. engages in the advanced medicinal treatment, site management organization, contract research organization, and medical support businesses in Japan. The company engages in the development of medical technologies, such as regenerative medicine and gene therapy for obstructive arteriosclerosis, retinitis pigmentosa, and human immunodeficiency virus infection and acquired immune deficiency syndrome, as well as Sendai virus vector and CytoTune-iPS, a kit for generating iPS cells. It also supports medical institutions in conducting clinical trials; provides clinical trial support services for new drug development and medical equipment for cancer, and rare and intractable diseases; and establishes and operates clinic malls. The company was formerly known as I'Rom Holdings Co., Ltd. and changed its name to I'rom Group Co., Ltd. in July 2015. I'rom Group Co., Ltd. was founded in 1997 and is headquartered in Tokyo, Japan.
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, neutral on EV/E